Precision Biosciences Inc (DTIL)

$7.44 -0.14 (-1.85%)
Market Cap 195.59M
Revenue (ttm) 34.26M
Net Income (ttm) -45.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -133.45%
Debt to Equity Ratio 0.24
Volume 139,200
Avg Vol 294,240
Day's Range N/A - N/A
Shares Out 25.80M
Stochastic %K 70%
Beta 1.09
Analysts Strong Sell
Price Target $32.67

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 314 5512
Fax: 480 393 5553
Address:
302 East Pettigrew St., Suite A-100, Durham, United States
Wolfman5960
Wolfman5960 Apr. 20 at 10:52 AM
$DTIL Next month should be interesting. The ASGCT conference is held from May 11-15 and the EASL Congress conference is May 27-30. iECURE will probably give an update at ASGCT and we should see an update from Precision for the HBV program at EASL.
0 · Reply
revuelto
revuelto Apr. 17 at 6:13 PM
$DTIL 🎉
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 15 at 6:48 PM
$DTIL $70 🚀
0 · Reply
DARKP00L
DARKP00L Apr. 15 at 11:13 AM
$DTIL 07:11 on Apr. 15 2026 Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV #tradeideas
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 14 at 12:33 PM
$SANA Good Morning 💎 s. $AMLX $RXRX $TEMT $DTIL ☕️
0 · Reply
MoonlitCocoa
MoonlitCocoa Apr. 10 at 12:14 PM
$DTIL
0 · Reply
Stonehands
Stonehands Apr. 9 at 10:31 PM
$DTIL The board here is quiet. The run up in March had great volume. It has petered out somewhat but looks like a handle forming?
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 7 at 7:20 PM
$DTIL 🚀 $AMLX $RXRX $SMMT
0 · Reply
CaliberPalaceTrades
CaliberPalaceTrades Apr. 2 at 3:06 PM
$DTIL is this affected by the new tarif coming out?
2 · Reply
YoloAlfred
YoloAlfred Mar. 24 at 2:54 PM
$DTIL 😎🖕
0 · Reply
Latest News on DTIL
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Apr 15, 2026, 7:01 AM EDT - 7 days ago

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 7:01 AM EDT - 14 days ago

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Mar 12, 2026, 7:00 AM EDT - 5 weeks ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Mar 11, 2026, 7:01 AM EDT - 6 weeks ago

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Mar 10, 2026, 7:01 AM EDT - 6 weeks ago

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Mar 9, 2026, 4:15 PM EDT - 6 weeks ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Mar 9, 2026, 7:01 AM EDT - 6 weeks ago

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

Mar 2, 2026, 7:01 AM EST - 7 weeks ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

TGTX

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 18, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Feb 11, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Jan 12, 2026, 7:01 AM EST - 3 months ago

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dec 23, 2025, 7:00 AM EST - 4 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Nov 19, 2025, 7:01 AM EST - 5 months ago

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov 10, 2025, 6:12 PM EST - 5 months ago

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Nov 10, 2025, 5:21 PM EST - 5 months ago

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:01 AM EST - 6 months ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 31, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Oct 14, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Oct 9, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Oct 7, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Sep 30, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 12, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Sep 8, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 6, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Aug 4, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 23, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jul 16, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jun 25, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 14, 2025, 4:30 PM EDT - 1 year ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 8, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 7, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 15, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 21, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 20, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 19, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 17, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Mar 12, 2025, 8:00 AM EDT - 1 year ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 24, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 2:27 PM EST - 1 year ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Feb 19, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 29, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 10, 2025, 2:18 PM EST - 1 year ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 10:01 AM EST - 1 year ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 1 year ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Dec 18, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Wolfman5960
Wolfman5960 Apr. 20 at 10:52 AM
$DTIL Next month should be interesting. The ASGCT conference is held from May 11-15 and the EASL Congress conference is May 27-30. iECURE will probably give an update at ASGCT and we should see an update from Precision for the HBV program at EASL.
0 · Reply
revuelto
revuelto Apr. 17 at 6:13 PM
$DTIL 🎉
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 15 at 6:48 PM
$DTIL $70 🚀
0 · Reply
DARKP00L
DARKP00L Apr. 15 at 11:13 AM
$DTIL 07:11 on Apr. 15 2026 Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV #tradeideas
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 14 at 12:33 PM
$SANA Good Morning 💎 s. $AMLX $RXRX $TEMT $DTIL ☕️
0 · Reply
MoonlitCocoa
MoonlitCocoa Apr. 10 at 12:14 PM
$DTIL
0 · Reply
Stonehands
Stonehands Apr. 9 at 10:31 PM
$DTIL The board here is quiet. The run up in March had great volume. It has petered out somewhat but looks like a handle forming?
0 · Reply
LoveRetailFroth
LoveRetailFroth Apr. 7 at 7:20 PM
$DTIL 🚀 $AMLX $RXRX $SMMT
0 · Reply
CaliberPalaceTrades
CaliberPalaceTrades Apr. 2 at 3:06 PM
$DTIL is this affected by the new tarif coming out?
2 · Reply
YoloAlfred
YoloAlfred Mar. 24 at 2:54 PM
$DTIL 😎🖕
0 · Reply
Bob_Whitley
Bob_Whitley Mar. 20 at 3:41 PM
$TGTX How is that $DTIL short doing these days? Looks like you got your face kicked in.
1 · Reply
steven1x
steven1x Mar. 18 at 5:02 PM
$DTIL is this it? https://www.businesswire.com/news/home/20260318998536/en/iECURE-Selected-for-U.S.-FDA-Chemistry-Manufacturing-and-Controls-Development-and-Readiness-Pilot-Program-to-Support-Manufacturing-Readiness-of-ECUR-506-Ahead-of-Planned-BLA-Submission
2 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 18 at 4:59 PM
$DTIL $70 🥪
0 · Reply
steven1x
steven1x Mar. 18 at 4:56 PM
$DTIL why the lift?
0 · Reply
AlphaOfBiotech
AlphaOfBiotech Mar. 18 at 4:12 PM
$DTIL $DTIL Go Go Go!!! Cheers 🥂 🥂🥂$FATE and $CRDF , which will be the next?
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 18 at 3:56 PM
$TGTX I think the smarter play right now is $DTIL
2 · Reply
DARKP00L
DARKP00L Mar. 18 at 12:08 PM
$DTIL 08:05 on Mar. 18 2026 iECURE's ECUR-506, And The Associated Nucleus Licensed From Precision BioSciences, Selected For FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program #tradeideas
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 18 at 11:11 AM
$DTIL $AMTX $XFOR been raising u up and lately $LNZA
0 · Reply
BiotechGoldenEra
BiotechGoldenEra Mar. 17 at 11:22 PM
$DTIL what a month
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 17 at 5:37 PM
$DTIL $XFOR CONTINUED TO PUSH U 2 UP
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Mar. 17 at 5:24 PM
$DTIL Somebody wishing they were the "Patient_Investor" right about now.
1 · Reply
topstockalerts
topstockalerts Mar. 17 at 5:16 PM
$DTIL When updates hit, this ticker can wake up fast. First wave of volume usually brings in short-term traders.
0 · Reply